A Phase 2 interventional study of teplizumab 1 mg/mL in Diabetes Mellitus, Type 1, sponsored by Provention Bio, a Sanofi Company. Completed at 8 sites in United States. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Provention Bio, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 2, and was the 7th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Abdullah Kars · Sites in Turkey
Ages 18–45
By country, each count listing its studies:
teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2020.
This study's enrollment of 6 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Provention Bio, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Provention Bio, a Sanofi Company is the lead sponsor of 4 studies on the registry; none are open to participants now.
67 studies in Diabetes Mellitus, Type 1 by Sanofi: 6 open now, 10 under way, 1 of them phase 3. Of 56 finished, 13 (23%) have results posted.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 58th largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2020, is one of 5 in phase 2, and was the 55th registered.
Sanofi’s Diabetes Mellitus, Type 1 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, from their registry updates:
Among Sanofi’s 67 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the conclusion of that trial, were eligible to enroll and receive teplizumab treatment within one year of diagnosis of clinical type 1 diabetes.
The study was a single-arm, multicenter, open-label clinical trial. All participants received a 12-day course of teplizumab given through daily IV infusion and were followed for 78 weeks.
The purpose of this study was to evaluate the safety and tolerability of teplizumab treatment, administered intravenously (IV) to participants in the NIH-sponsored trial who have developed type 1 diabetes and were able to start teplizumab treatment within 1 year of diagnosis of type 1 diabetes. Whether teplizumab treatment reduced the loss of insulin-producing pancreatic beta cells were evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration of teplizumab by intravenous infusion for 12 consecutive days
Drug: teplizumab 1 mg/mL
Drug page: Teplizumab
Solution for infusion administered as IV infusion (anti-CD3 humanized monoclonal antibody). Cumulative dose: 9 mg/m2. Day 1: 106 μg/m2, Day 2: 425 μg/m2, Days 3-12: 850 μg/m2 daily
Also known as: PRV-031, Tzield
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Adverse Events of Special Interest (TEAESIs) and Treatment-emergent Serious Adverse Events (TESAEs)
An AE was any untoward medical occurrence in a participant or clinical study participant,temporally associated with use of study dose,whether or not considered related to study dose.AESI was any AE that met any of following:All \>=Grade 3 infections (including all opportunistic infections);acute mononucleosis-like illness;lymphomas or other malignancies;severe hypoglycemic episode;\>=Grade 3 liver function abnormalities, thrombocytopenia, neutropenia or rash;\>= Grade 4 allergic/hypersensitivity reaction (anaphylaxis) or cytokine-release syndrome; lymphocyte count \<500/cubic millimeter for 7 days or longer. An SAE was as any untoward medical occurrence that,at any dose:resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization,resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or any other medically important event.A TEAE was any AE which started during or after the first dose of teplizumab.
Time frame: From the first dose of study drug administration (Day 1) up to approximately 78 weeks
Serum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of Teplizumab at Day 364
Blood samples were collected for evaluation of pharmacokinetic (PK) data.
Time frame: Pre-dose on Day 364
Number of Participants With Anti-drug Antibodies (ADA) Against Teplizumab
Blood samples were collected for the evaluation of ADA against teplizumab.
Time frame: Up to Day 364
Area Under the Time-Versus-Concentration Curve (AUC) of C-peptide After a 4-hour (4h) Mixed Meal Tolerance Test (MMTT) at Week 78
The AUC of C-peptide was measured after a 4-hour MMTT as a measure of assessing endogenous insulin production and beta cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test for the analysis.
Time frame: Week 78
Glycated Hemoglobin (HbA1c) Levels at Week 78
Blood samples were collected for evaluation of HbA1c.
Time frame: Week 78
Average Daily Use of Exogenous Insulin at Week 78
The average daily insulin use was calculated based on participants who had at least 3 days of insulin use recorded in the diary for the Week 78 visit.
Time frame: Week 78
Number of Participants With Severe Hypoglycemic Episodes
The severity of a hypoglycemia event was identified by the Investigator and classified according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 as follows: * Grade 3 hypoglycemia: 30-39 milligram/deciliter (mg/dL) (1.7-2.1 millimole \[mmol\]/L). This is considered severe or medically significant but not immediately life-threatening. Hospitalization or prolongation of hospitalization is likely indicated. It is considered disabling and limits self-care. * Grade 4 hypoglycemia: \<=29 mg/dL (1.6 mmol/L). This is considered life threatening (seizures) with urgent intervention indicated. * Grade 5 hypoglycemia: Hypoglycemia resulting in death. Hypoglycemia \>=Grade 3 was considered as severe hypoglycemia.
Time frame: From the first dose of study drug administration (Day 1) up to approximately 78 weeks
Number of Participants With Change in Cluster of Differentiation (CD)8+ TIGIT+ KLRG1+ T Cells
CD8+ TIGIT+ KLRG1+ T cells were measured using flow cytometry.
Time frame: From the first dose of study drug administration (Day 1) up to approximately 78 weeks
The study was conducted in the United States from 26-Feb-2020 to 22-Jan-2024.
| Milestone | Teplizumab |
|---|---|
| Started | 6 |
| Completed | 5 |
| Not completed | 1 |
| Withdrew: Death | 1 |
An AE was any untoward medical occurrence in a participant or clinical study participant,temporally associated with use of study dose,whether or not considered related to study dose.AESI was any AE that met any of following:All \>=Grade 3 infections (including all opportunistic infections);acute mononucleosis-like illness;lymphomas or other malignancies;severe hypoglycemic episode;\>=Grade 3 liver function abnormalities, thrombocytopenia, neutropenia or rash;\>= Grade 4 allergic/hypersensitivity reaction (anaphylaxis) or cytokine-release syndrome; lymphocyte count \<500/cubic millimeter for 7 days or longer. An SAE was as any untoward medical occurrence that,at any dose:resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization,resulted in persistent disability/incapacity, was a congenital anomaly/birth defect or any other medically important event.A TEAE was any AE which started during or after the first dose of teplizumab.
| Participants | Teplizumab |
|---|---|
| Any TEAE | 6 |
| Any TEAESI | 0 |
| Any TESAE | 1 |
Blood samples were collected for evaluation of pharmacokinetic (PK) data.
| nanogram/milliliter (ng/mL) | Teplizumab |
|---|---|
| Serum Concentration Immediately Prior to Administration of the Next Dose (Ctrough) of Teplizumab at Day 364 | NA ± NA |
Blood samples were collected for the evaluation of ADA against teplizumab.
| Participants | Teplizumab |
|---|---|
| Number of Participants With Anti-drug Antibodies (ADA) Against Teplizumab | 6 |
The AUC of C-peptide was measured after a 4-hour MMTT as a measure of assessing endogenous insulin production and beta cell function. The AUC was computed using the trapezoidal rule and standardized by the duration of the MMTT test for the analysis.
| ln(AUC+1) (picomole/mL) | Teplizumab |
|---|---|
| Area Under the Time-Versus-Concentration Curve (AUC) of C-peptide After a 4-hour (4h) Mixed Meal Tolerance Test (MMTT) at Week 78 | 0.549 ± 0.4276 |
Blood samples were collected for evaluation of HbA1c.
| percentage of HbA1c | Teplizumab |
|---|---|
| Glycated Hemoglobin (HbA1c) Levels at Week 78 | 8.50 ± 3.785 |
The average daily insulin use was calculated based on participants who had at least 3 days of insulin use recorded in the diary for the Week 78 visit.
| unit/kilogram/day | Teplizumab |
|---|---|
| Average Daily Use of Exogenous Insulin at Week 78 | 0.54 ± 0.357 |
The severity of a hypoglycemia event was identified by the Investigator and classified according to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 as follows: * Grade 3 hypoglycemia: 30-39 milligram/deciliter (mg/dL) (1.7-2.1 millimole \[mmol\]/L). This is considered severe or medically significant but not immediately life-threatening. Hospitalization or prolongation of hospitalization is likely indicated. It is considered disabling and limits self-care. * Grade 4 hypoglycemia: \<=29 mg/dL (1.6 mmol/L). This is considered life threatening (seizures) with urgent intervention indicated. * Grade 5 hypoglycemia: Hypoglycemia resulting in death. Hypoglycemia \>=Grade 3 was considered as severe hypoglycemia.
| Participants | Teplizumab |
|---|---|
| Number of Participants With Severe Hypoglycemic Episodes | 0 |
CD8+ TIGIT+ KLRG1+ T cells were measured using flow cytometry.
| Participants | Teplizumab |
|---|---|
| Number of Participants With Change in Cluster of Differentiation (CD)8+ TIGIT+ KLRG1+ T Cells | 4 |
Collected over From the first dose of study drug administration (Day 1) up to approximately 78 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teplizumab | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Teplizumab |
|---|---|
| Completed SuicidePsychiatric disorders | 1/6 |
| Event | Teplizumab |
|---|---|
| HeadacheNervous system disorders | 4/6 |
| LymphopeniaBlood and lymphatic system disorders | 3/6 |
| NauseaGastrointestinal disorders | 3/6 |
| LeukopeniaBlood and lymphatic system disorders | 2/6 |
| VomitingGastrointestinal disorders | 2/6 |
| PyrexiaGeneral disorders | 2/6 |
| RashSkin and subcutaneous tissue disorders | 2/6 |
| NeutropeniaBlood and lymphatic system disorders | 1/6 |
| BradycardiaCardiac disorders | 1/6 |
| ChillsGeneral disorders | 1/6 |
The safety analysis set included all participants who received at least 1 dose of teplizumab.
| Age, Continuous(years) | Teplizumab |
|---|---|
| Mean | 21.3 ± 11.59 |
| Sex: Female, Male(Participants) | Teplizumab |
|---|---|
| Female | 3 |
| Male | 3 |
| Race (NIH/OMB)(Participants) | Teplizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Feb 2020 to primary completion in Jan 2024, 46 months.
Results were first posted in Feb 2025, 1 year after primary completion.
Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 46 months is above that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teplizumab